S. Markmann

发表

Sorafenib plus topotecan versus placebo plus topotecan for platinum-resistant ovarian cancer (TRIAS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.

Marcus Schmidt, J. Sehouli, P. Harter, 2018, The Lancet. Oncology.

Adjuvant sequential chemoradiation therapy in high-risk endometrial cancer: results of a prospective, multicenter phase-II study of the NOGGO (North-Eastern German Society of Gynaecological Oncology)

H. Sommer, W. Lichtenegger, J. Sehouli, 2013, Cancer Chemotherapy and Pharmacology.

WSG PLAN B trial: Evaluating efficacy of anthracycline-free chemotherapy in primary HER2-negative breast cancer after molecular-based risk assessment according to Oncotype DX and uPA/PAI-1.

N. Harbeck, O. Gluz, C. Liedtke, 2010 .

Topotecan Weekly Versus Conventional 5-Day Schedule in Patients With Platinum-Resistant Ovarian Cancer: a randomized multicenter phase II trial of the North-Eastern German Society of Gynecological Oncology Ovarian Cancer Study Group.

H. Sommer, W. Lichtenegger, J. Sehouli, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Effectiveness of Trastuzumab (HerceptinTM) in a Patient with Locally Recurrent Breast Cancer after Cardiac Failure Caused by Severe Cytotoxic Pretreatment

T. Reimer, R. Fietkau, B. Gerber, 2001, Oncology.

S4-3: Prospective Comparison of Risk Assessment Tools in Early Breast Cancer (Recurrence Score, uPA/PAI-1, Central Grade, and Luminal Subtypes): Final Correlation Analysis from the Phase III WSG-Plan B Trial.

S. Shak, N. Harbeck, O. Gluz, 2011 .

A prospective multicenter study of treosulfan in elderly patients with recurrent ovarian cancer: results of a planned safety analysis

H. Kölbl, H. Sommer, J. Sehouli, 2012, Journal of Cancer Research and Clinical Oncology.

The safety of synthetic paclitaxel by intralesional delivery with OncoGel™ into skin breast cancer metastases: method and results of a clinical pilot trial

A. Schindler, M. Scheulen, B. Gerber, 2005, Archives of Gynecology and Obstetrics.

The 21-gene recurrence score assay impacts adjuvant therapy recommendations for ER-positive, node-negative and node-positive early breast cancer resulting in a risk-adapted change in chemotherapy use

M. Rezai, A. Schneeweiss, T. Kühn, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

Unilateral ovarian agenesis: report of three cases and review of the literature

K. Friese, I. Mylonas, S. Markmann, 2003, Archives of Gynecology and Obstetrics.

Adjuvant sequential chemo-radiation therapy in high-risk endometrial cancer: Results of a prospective, multicenter phase II study of the NOGGO.

H. Sommer, J. Sehouli, M. Zygmunt, 2011, Journal of Clinical Oncology.

Abstract P2-10-08: Prospective comparison of Recurrence Score and different definitions of luminal subtypes by central pathology assessment of single markers in early breast cancer: results from the phase III WSG-planB Trial

S. Shak, N. Harbeck, O. Gluz, 2012 .

Prognostic value of Ca 125 levels during primary therapy.

B. Gerber, S. Markmann, V. Briese, 2007, Anticancer research.

How Important is the Axillary Nodal Status for Adjuvant Treatment Decisions at a Breast Cancer Multidisciplinary Tumor Board? A Survival Analysis

T. Reimer, R. Fietkau, B. Gerber, 2007, Annals of Surgical Oncology.

The Endocrine Treatment Landscape for Patients with HR+ HER2− Early-stage Breast Cancer in Germany Before the Introduction of CDK4/6 Inhibitor Therapy – A Real-World Analysis

N. Nabieva, F. Kiss, A. Belau, 2023, Geburtshilfe und Frauenheilkunde.

Prospective comparison of recurrence score and independent central pathology assessment of prognostic tools in early breast cancer (BC): Focus on HER2, ER, PR, Ki-67 results from the phase III WSG-Plan B trial.

S. Shak, N. Harbeck, O. Gluz, 2012 .

Topotecan weekly versus routine 5-day schedule in patients with platinum-resistant ovarian cancer (TOWER): A randomized, two-stage phase-II study of the North-Eastern German Society of Gynaecological Oncology (NOGGO)

S. Loibl, W. Lichtenegger, J. Sehouli, 2007 .

Severe acute motor neuropathy after treatment with triple tyrosine kinase inhibitor BIBF 1120 (Nintedanib)

R. Benecke, M. Wittstock, S. Markmann, 2013, Clinical neurology and neurosurgery (Dutch-Flemish ed. Print).

The Endocrine Treatment Landscape for Patients with HR+ HER2− Early-stage Breast Cancer in Germany Before the Introduction of CDK4/6 Inhibitor Therapy – A Real-World Analysis

N. Nabieva, F. Kiss, A. Belau, 2023, Geburtshilfe und Frauenheilkunde.

Topotecan weekly versus routine 5-day schedule in patients with platinum-resistant ovarian cancer (TOWER): A randomized, multicenter trial of the North-Eastern German Society of Gynecological Oncology (NOGGO).

W. Lichtenegger, J. Sehouli, P. Harter, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.